ArticleScientific reports2026
Enhanced antimicrobial and anticancer properties of penicillin G-adapted Lacticaseibacillus rhamnosus GG against colorectal cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most prevalent cancers globally, ranking third in women and fourth in men, and accounts for approximately 10% of cancer-related deaths. Antibiotic therapy and chemotherapy are common treatments for intestinal diseases and CRC, but they can affect the gut microbiota and cause dysbiosis. Probiotics are vital for maintaining a healthy gut microbiota and preventing dysbiosis. Lacticaseibacillus rhamnosus GG (L. rhamnosus) is well-known for its antimicrobial and anticancer properties.
methodsIn the present study, we aimed to investigate the effects of long-term penicillin G treatment on the antimicrobial and anticancer properties of L. rhamnosus. Initially, an antibiotic-resistant L. rhamnosus was created by the adaptation process. The acid tolerance of both antibiotic-resistant and normal strains was assessed. The antimicrobial properties of the cell-free supernatants (CFS) from both untreated and penicillin G-treated strains (Pen(G)-CFS) on different species of pathogenic bacteria, including Staphylococcus epidermidis (CoNS), Staphylococcus aureus, Enterococcus faecalis, Salmonella typhi, Escherichia coli, and Pseudomonas aeruginosa were investigated. To assess the anticancer effects of these supernatants on HT-29 CRC cells, various cellular and molecular assays, including MTT, apoptosis (Annexin V/PI staining), cell cycle, scratch, and colony formation assays, quantitative real-time PCR (qRT-PCR), and Western blot were performed.
resultsOur results demonstrated no significant difference in proliferation between the two strains in acidic conditions. Interestingly, Pen(G)-CFS exhibited a significantly stronger antimicrobial effect against pathogenic bacteria compared to the CFS. The results of cellular experiments showed that treating HT-29 cells with Pen(G)-CFS compared to CFS could significantly inhibit proliferation. Additionally, this treatment increased the rate of apoptosis, arrested the cell cycle in the sub-G1 phase, and suppressed cell migration and colony formation ability. These findings were confirmed using qRT-PCR and western blot analysis, which revealed Pen(G)-CFS could considerably modulate the expression of genes and proteins (BAX, BCL2, CASP3, CASP9, MMP3, MMP9) compared with CFS.
conclusionsOur results suggest that antibiotic-resistant L. rhamnosus not only retains probiotic properties but also exhibits enhanced antimicrobial and anticancer activities compared to the normal strain. This approach holds promise for reducing the adverse effects of antibiotics and chemotherapy on the gut microbiota and may offer a novel strategy for improving patient outcomes in CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.